Authors
Latest:
Managing Prostate Cancer Surgical Patients during the COVID-19 Pandemic: A Brief Report of the Duke Cancer Institute’s Initial ExperienceExperts from the Duke Cancer Institute outline their current approach to stratifying surgical management of patients with prostate cancer.
Latest:
Immune-Related Adverse Events Involving Multiple Organ Sites in a Patient Treated With Nivolumab Plus IpilimumabExperts discuss the case of a 56-year-old white man who presents with multiple immune-related adverse events
Latest:
Association of Financial Conflicts of Interest With Academic Productivity Among Junior Faculty in Hematology and OncologyConflicts of interest for junior faculty members were evaluated at top cancer centers by Suneel D. Kamath, MD, et al. to determine how financial conflicts of interest correlated with measures of academic career productivity.
Latest:
Sotorasib Demonstrates Promising Antitumor Activity in Advanced NSCLCSotorasib showed promising antitumor activity in patients with non-small cell lung cancer that harbor the KRAS p.G12C mutation.
Latest:
FDA OKs Zanubrutinib to Treat Leukemia SubtypesPatients with chronic lymphocytic leukemia and small lymphocytic leukemia can now receive treatment with zanubrutinib following its approval by the FDA.
Latest:
Mirvetuximab Yields HRQOL Improvement in FRα-Positive Ovarian CancerPatient reported outcomes from the phase 3 MIRASOL trial showed improvement when mirvetuximab was used vs standard of care in folate receptor-alpha positive ovarian cancer resistant ovarian cancer.
Latest:
Stephen Schuster, MD, Gives Advice for Treating Aggressive Lymphomas During COVID-19 PandemicStephen Schuster, MD, talked about the benefits of conducting routine visits remotely during the COVID-19 pandemic, allowing doctors to see and treat more patients safely and efficiently.
Latest:
Greater Sleep Disturbance Associated With External Factors in Patients With GI CancersIn patients with gastrointestinal cancers, factors such as younger age and comorbidities, among others, were significantly associated with a greater likelihood of sleep disturbance.
Latest:
Circulating KIM-1 May Predict Benefit With Atezolizumab in RCCKIM-1 was the most significantly enriched circulating protein in recurrence vs baseline serum samples among patients in the IMmotion010 trial.
Latest:
Expanding and Advancing the Future of Renal Cell Carcinoma TreatmentEric Jonasch, MD, believes that the Kidney Cancer Research Consortium may broaden their reach to provide care to many different groups of patients.
Latest:
Amir Goldkorn, MD Talks Next Steps for SWOG 1216 TrialThe University of Southern California expert discusses next steps for the trial and how the recent results could impact the future of care for patients with prostate cancer.
Latest:
Courtney DiNardo, MD, on Looking Forward in AML TreatmentThe MD Anderson Cancer Center expert discussed the future of acute myeloid leukemia treatment, and how the field is evolving rapidly.
Latest:
Kelly Morgan, MS, CGC, the Future of Telemedicine and Genetic TestingThe MSK expert discussed how telemedicine may change genetic testing and its access for patients.
Latest:
Matthew Steven Davids, MD, MMSc, on the Venetoclax, R-EPOCH Combo for Richter’s SyndromeThe CLL expert spoke about the implications of this study for patients and how patients can apply this knowledge to their own course of treatment.
Latest:
Thierry André, MD, on Interim Results from the Phase III Keynote-177 StudyThe findings, presented at the 2020 ASCO Virtual Scientific Program, are the first to show benefit with pembrolizumab in patients with advanced colorectal cancer when used as a front-line therapy.
Latest:
Benoit You, MD, PhD, on the use of Avelumab to Treat Patients With Gestational Trophoblastic TumorsThe expert from the Centre Hospitalier Lyon-Sud discussed the results of a phase II study of avelumab for patients with GTT who were resistant to chemotherapy.
Latest:
John Kuruvilla, MD, Discusses Toxicities Observed in the Phase 3 KEYNOTE-204 StudyThe expert in hematology highlighted the toxicities reported in this trial and explained the differences observed between the 2 drugs studied.
Latest:
Dosing Lenvatinib for Treatment of Advanced Renal Cell CarcinomaKidney cancer experts explain how they dose lenvatinib in advanced renal cell carcinoma treatment to mitigate toxicities.
Latest:
Sacituzumab Govitecan Yields Improved Survival Regardless of Trop-2 Levels for HR+/HER2– Breast CancerImprovements in survival were observed in patients with pretreated, endocrine-resistant hormone receptor–positive, HER2-negative metastatic breast cancer who were treated with sacituzumab govitecan vs physician’s choice.
Latest:
Andres Poveda, MD, on the Implications of the Phase 3 SOLO2/ENGOT-ov21 TrialThe expert in ovarian cancer indicated that treatment with the studied maintenance olaparib tablets could aid patients in having a more regular lifestyle.
Latest:
JNJ-79635322 Shows Safety/Favorable Responses in R/R Multiple MyelomaThe 1-year progression-free survival rate for patients in the BCMA/GPRC5D naïve RP2D group was 95.0% and across all dose levels it was 74.1%.
Latest:
Olaparib/Radium-223 Combination Demonstrates Feasibility and Antitumor Activity in CRPCThe combination of olaparib and radium-223 improved rPFS in castration-resistant prostate cancer without prior docetaxel treatment or with fewer than 20 bone metastases.
Latest:
Olaparib/Radium-223 Combination Demonstrates Feasibility and Antitumor Activity in CRPCThe combination of olaparib and radium-223 improved rPFS in castration-resistant prostate cancer without prior docetaxel treatment or with fewer than 20 bone metastases.
Latest:
ASCO Expert on the Possible Benchmark Analysis of Autologous Transplantation in B-Cell LymphomasNirav Niranjan Shah, MD, discussed the analysis of autologous transplantation use in patients with relapsed, chemosensitive DLBCL and how it may become a comparator for other clinical trials.
Latest:
Cross Q&A: The Memorial Sloan-Kettering MavericksThe Moffitt Marrowvingians take their turn questioning the Memorial Sloan Kettering Mavericks on their presented clinical trial data.
Latest:
The Role of Autologous Stem Cell Transplantation in AmyloidosisAutologous stem cell transplantation has been an essential part of the treatment armamentarium in light chain amyloidosis for several decades. This review provides a comprehensive assessment of eligibility criteria for ASCT in AL amyloidosis, conditioning dosing, efficacy in terms of hematologic and organ response, and future areas of research.
Latest:
Martin Reck, MD, PhD, Discusses NSCLC Data of Interest From 2021 ASCOReck mentioned the IMpower010 and CheckMate 816 trials investigating treatment options for patients with non-small cell lung cancer.
Latest:
Reflecting on Unmet Needs in Multiple Myeloma After IMS 2022Closing out their discussion, the panel highlights unmet needs in multiple myeloma that clinicians and patients still face.
